Patents by Inventor Hui Feng

Hui Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240235229
    Abstract: This application provides a method and an apparatus for detecting an electric charging gun mounting status. In the technical solutions provided in this application, a charging device obtains a first voltage value at a first connection confirmation detection point and a second voltage value at a second connection confirmation detection point in a control and guiding circuit of a first charging gun, and obtains a third voltage value at a first connection confirmation detection point and a fourth voltage value at a second connection confirmation detection point in a control and guiding circuit of a first charging socket; and then determines an electric charging gun mounting status of the first charging gun and an electric charging gun mounting status of the first charging socket based on the first voltage value, the second voltage value, the third voltage value, and the fourth voltage value.
    Type: Application
    Filed: March 22, 2024
    Publication date: July 11, 2024
    Inventors: Zhouyang LIU, Xinlong ZHANG, Quan LI, Hui FENG
  • Publication number: 20240218066
    Abstract: The present disclosure relates to a method of an anti-PD-1 antibody in combination with first-line chemotherapy in the treatment of advanced non-small cell lung cancer. Specifically, the present disclosure relates to use of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and a first-line chemotherapeutic agent in the preparation of a drug for treating non-small cell lung cancer (NSCLC). The present disclosure also relates to a related drug combination and a kit.
    Type: Application
    Filed: April 21, 2022
    Publication date: July 4, 2024
    Applicant: SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
    Inventors: Sheng YAO, Hui FENG
  • Patent number: 12013772
    Abstract: Some embodiments include a system, method, and non-transitory medium, with the system including an interface to at least one database product; a stateless ping operator to manage lifecycle events associated with the at least one database product; and a first product-specific ping agent to determine an availability of and generate metrics associated with a plurality of instances of a first specific database product of the at least one database product monitored by the first product-specific ping agent, the first product-specific ping agent receiving an assignment of the plurality of instances of the first specific database product to monitor from the ping operator.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: June 18, 2024
    Assignee: SAP SE
    Inventors: Sunyoung Han, Young Hun Kim, Jongheon Park, Ye Fan, Guanghui Qiu, Hui Feng, Chul Won Lee
  • Patent number: 11980454
    Abstract: A system for measurements and calculations of a microcirculatory high-velocity blood flow includes a data acquisition module configured to select and acquire microcirculatory blood vessel image data; a storage module configured to store the acquired microcirculatory blood vessel image data; a velocity measurement module configured to measure a traveling distance and a traveling time of red blood cell (RBC), white blood cell (WBC), or plasma particles in a blood vessel sample and calculate a ratio of the traveling distance to the traveling time to obtain a blood flow velocity; and a high-velocity blood flow index module configured to determine an index level for the microcirculatory high-velocity blood flow. Specifically, an initial threshold, i.e. 1000 ?m/s, for the microcirculatory high-velocity blood flow of sepsis is proposed, which facilitates early diagnosis on sepsis. The changing process of the high-velocity blood flow shows development of the early-stage, intermediate-stage and end-stage sepsis.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: May 14, 2024
    Assignee: XUZHOU LIHUA ELECTRONIC TECHNOLOGY DEVELOPMENT CO., LIMITED
    Inventors: Xinghuai Feng, Hui Feng, Jie Shao, Jing Lu, Yuanchang Zhang
  • Patent number: 11971797
    Abstract: A digital mirroring method includes creating a digital model for each physical device of a plurality of physical devices located in a physical space. Once a related data of each physical device is obtained, the related data of each physical device is mapped to corresponding digital model.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: April 30, 2024
    Assignees: Fu Tai Hua Industry (Shenzhen) Co., Ltd., HON HAI PRECISION INDUSTRY CO., LTD.
    Inventors: Xin Lu, Fu-Fa Cai, Hui-Feng Liu
  • Publication number: 20240131952
    Abstract: This application provides a charging plug and socket-outlet, charging and to-be-charged apparatuses, a charging system, and a control method. The charging system includes: a charging apparatus and a to-be-charged apparatus. The charging apparatus includes a charging plug and a first cooling system. The charging plug includes a first electrical transmission interface, a first heat conduction output interface, and a first heat conduction input interface. The to-be-charged apparatus includes a battery, a charging socket-outlet, and a second cooling system. The charging socket-outlet includes a second electrical transmission interface, a second heat conduction output interface, and a second heat conduction input interface. The solutions of this application can be used to meet a heat dissipation requirement of the battery in the to-be-charged apparatus during super charging.
    Type: Application
    Filed: December 28, 2023
    Publication date: April 25, 2024
    Inventors: Deyuan Wang, Hui Feng, Liwen Pan
  • Publication number: 20240117043
    Abstract: The present disclosure provides a bispecific antibody including a binding domain that binds to CD112R and a binding domain that binds to TIGIT, and the binding domain that binds to CD112R includes: HCDR1, HCDR2 and HCDR3 of the amino acid sequence set forth in SEQ ID NO: 1, and/or LCDR1, LCDR2 and LCDR3 of the amino acid sequence set forth in SEQ ID NO: 2; and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system. The present disclosure further provides a polynucleotide encoding the antibody, an expression vector, a host cell and a method for expressing and purifying the antibody, a pharmaceutical composition including the antibody of the present disclosure, and use of the bispecific antibody for treating cancer.
    Type: Application
    Filed: August 4, 2023
    Publication date: April 11, 2024
    Applicants: SHANGHAI JUNSHI BIOSCIENCES CO., LTD., SUZHOU JUNMENG BIOSCIENCES CO., LTD.
    Inventors: Dandan LIU, Jinwei ZHOU, Yuehua ZHOU, Jing ZHANG, Sheng YAO, Hui FENG, Hui LIU, Hongchuan LIU, Li LI, Qiang ZHAO
  • Publication number: 20240067720
    Abstract: A stable anti-TIGIT antibody pharmaceutical composition and an application thereof. The pharmaceutical composition includes a buffer solution, and an anti-TIGIT antibody or an antigen-binding fragment thereof. The anti-TIGIT antibody or the antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3 having amino acid sequences as respectively represented by SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and LCDR1, LCDR2, and LCDR3 having amino acid sequences as respectively represented by SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. The pH of the pharmaceutical composition is about 5.0-6.5.
    Type: Application
    Filed: January 14, 2022
    Publication date: February 29, 2024
    Applicants: SHANGHAI JUNSHI BIOSCIENCES CO., LTD., SUZHOU JUNMENG BIOSCIENCES CO., LTD.
    Inventors: Peixiang LIU, Hongchuan LIU, Jing ZHANG, Qiang ZHAO, Hui FENG
  • Publication number: 20240026056
    Abstract: The present disclosure relates, according to some embodiments, to photostable photoactive compositions comprising (a) at least one photoactive compound that develops within itself an excited state energy when subjected to UV radiation and (b) a block copolymer comprising a plurality of blocks, wherein the block copolymer is operable to quench the excited state energy.
    Type: Application
    Filed: August 9, 2023
    Publication date: January 25, 2024
    Inventors: Hui Feng, Shengkui Hu, Dennis Zlotnik
  • Publication number: 20230365691
    Abstract: The present invention relates to the use of an anti-PD-1 antibody or an antigen-binding fragment thereof in preparing a drug for preventing or treating a malignant cancer, and the use of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and gemcitabine-cisplatin in preparing a drug for preventing or treating a malignant cancer. The malignant cancer is preferably nasopharyngeal carcinoma. The present invention also relates to a method for using a biomarker to predict the therapeutic effect of the anti-PD-1 antibody or the antigen-binding fragment thereof in treatment of nasopharyngeal carcinoma.
    Type: Application
    Filed: August 26, 2021
    Publication date: November 16, 2023
    Inventors: Sheng Yao, Hui Feng
  • Patent number: 11815912
    Abstract: A stability control method and device based on particle active disturbance rejection are provided. The method includes: establishing an active disturbance rejection controller model based on a dynamic model and a speed loop control model of a tethered balloon system, where the speed loop control model is established through theoretical modeling of executive components of a control system of the tethered balloon system; and optimizing to-be-optimized parameters of the active disturbance rejection controller model using a particle swarm optimization algorithm, determining an optimal active disturbance rejection controller model, and using the optimal active disturbance rejection controller model to implement stability control of a photoelectric pod. An active disturbance rejection controller is optimized by using a particle swarm optimization algorithm, which can effectively isolate the internal and external disturbances of the photoelectric pod and improve the imaging stability of the photoelectric pod.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: November 14, 2023
    Assignee: Aerospace Information Research Institute, Chinese Academy of Sciences
    Inventors: Hui Feng, Jiacheng Ma, Sheng Wang, Lei Ao, Xiangqiang Zhang, Tao Qiao
  • Patent number: 11796795
    Abstract: The invention provides a method for designing a diffractive optical element, characterized in comprising: S101: obtaining a first optical field pattern on a target plane; S102: converting the first optical field pattern on the target plane into a second optical field pattern on a spherical surface; S103: compensating for missing points of the second optical field pattern on the spherical surface, and matching grayscale values, so as to obtain a corrected third optical field pattern; and S104: obtaining a phase distribution of the diffractive optical element according to the third optical field pattern. By means of the design method, the projection quality of a diffractive optical element is improved.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: October 24, 2023
    Assignee: JIAXING UPHOTON OPTOELECTRONICS TECHNOLOGY CO., LTD.
    Inventors: Hui Feng, Hui Zhao
  • Publication number: 20230322929
    Abstract: The present disclosure relates to the use of an anti-BTLA antagonist (including antibodies and antigen binding fragments) in the treatment of various tumors, either as a mono therapy or a combination therapy with other immune checkpoint inhibitor therapy such as anti-PD-1 or anti-PD-L1, and methods of selecting subjects in need of treatment. Preferably, various solid tumors are treated.
    Type: Application
    Filed: April 10, 2023
    Publication date: October 12, 2023
    Applicant: SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
    Inventors: Sheng YAO, Hui FENG
  • Publication number: 20230322930
    Abstract: Provided are a combination of an anti-PD-1 antibody or an antigen binding fragment of the anti-PD-1 antibody and a cytotoxic anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer. Specifically, Provided are a combination of an anti-PD-1 antibody or an antigen-binding fragment of the anti-PD-1 antibody, an anti-folate metabolism anticancer drug, and a platinum anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer that has failed EGFR-TKI treatment.
    Type: Application
    Filed: August 27, 2021
    Publication date: October 12, 2023
    Inventors: Sheng Yao, Hui Feng
  • Publication number: 20230306894
    Abstract: An image processing method, for processing image data to be displayed by a display panel having a display area being divided into multiple sub-areas, including: determining a power-saving ratio for each sub-area according to a power-saving level; and sequentially adjusting image data of each sub-area in the original image data according to the power-saving ratio corresponding to said sub-area to generate output image data. In the output image data, a characteristic value of the image data corresponding to one of the sub-areas is reduced.
    Type: Application
    Filed: December 7, 2022
    Publication date: September 28, 2023
    Applicant: NOVATEK Microelectronics Corp.
    Inventors: Hui-Feng Lin, Yen-Tao Liao
  • Patent number: 11767392
    Abstract: The present disclosure relates, according to some embodiments, to photostable photoactive compositions comprising (a) at least one photoactive compound that develops within itself an excited state energy when subjected to UV radiation and (b) a block copolymer comprising a plurality of blocks, wherein the block copolymer is operable to quench the excited state energy.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: September 26, 2023
    Assignee: HALLSTAR BEAUTY AND PERSONAL CARE INNOVATIONS COMPANY
    Inventors: Hui Feng, Shengkui Hu, Dennis Zlotnik
  • Publication number: 20230295301
    Abstract: An antibody specifically binding to CTLA-4 or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or an antigen-binding fragment thereof, and therapcutic and diagnostic methods and the use of the antibody or an antigen-binding fragment thereof.
    Type: Application
    Filed: July 21, 2021
    Publication date: September 21, 2023
    Inventors: Zhiwei PAN, Jian YAO, Jing ZHANG, Yuehua ZHOU, Hongchuan LIU, Hai WU, Sheng YAO, Hui FENG
  • Publication number: 20230211697
    Abstract: An example vehicle charging method includes: obtaining a status of a first battery pack in a first mobile charging facility; in response to determining that the first battery pack is in a charging state or a fully charged state, obtaining a second state of energy sent by a second mobile charging facility, where the second mobile charging facility is charging a first vehicle, and the second state of energy is a state of energy of a second battery pack in the second mobile charging facility; and in response to at least that a first state of energy and the second state of energy meet a first preset condition, sending a first indication signal to the first mobile charging facility for indicating the first mobile charging facility to charge the first vehicle.
    Type: Application
    Filed: March 10, 2023
    Publication date: July 6, 2023
    Inventors: Hongpu XIA, Hui FENG, Yalin LIU
  • Publication number: 20230212292
    Abstract: The present disclosure relates to use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in the treatment of a neuroendocrine neoplasm. The present disclosure also relates to an agent or a kit for detecting an ARID1A gene mutation or amplification, or a chromosomal gene rearrangement, and use of the detection agent or kit in predicting the therapeutic effect of an anti-PD-1 antibody or an antigen-binding fragment thereof in the treatment of a patient with a neuroendocrine neoplasm.
    Type: Application
    Filed: February 10, 2021
    Publication date: July 6, 2023
    Inventors: Sheng YAO, Hui Feng, Hai Wu
  • Patent number: D1007957
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: December 19, 2023
    Inventor: Hui-Feng Yang